½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1600098

½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå : µð¹ÙÀ̽º À¯Çü, °Ë»ç À¯Çü, ±â¼ú, ¿ëµµº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Heart Failure POC & LOC Devices Market by Device Type (Lab-on-a-Chip (LOC) Devices, Point-of-Care (POC) Devices), Test Type (Genomic Testing, Metabolomic Testing, Proteomic Testing), Technology, Application - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀåÀº 2023³â¿¡ 9,613¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 1¾ï 887¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 14.45%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 2¾ï 4,737¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÉºÎÀü POC(Point-of-Care) ¹× LOC(Lab-on-Chip) Àåºñ´Â Á¶±â ¹ß°ßÀ» À§ÇØ ¼³°èµÈ ÇÚµåÇïµå ¹× ÈÞ´ë¿ë Àåºñ¸¦ Æ÷°ýÇϸç, ȯÀÚ°¡ ÀÖ´Â °÷¿¡¼­ ½Å¼ÓÇÏ°í Á¤È®ÇÑ Áø´ÜÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ½ÉÀå Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. POC ¹× LOC ±â±âÀÇ Çʿ伺Àº Àα¸ÀÇ °í·ÉÈ­, ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­, ±×¸®°í ÀÌ·Î ÀÎÇÑ ÀÇ·áºñ ºÎ´ãÀ¸·Î ÀÎÇØ ½ÉÀåÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÏ°í ÀÖÀ¸¹Ç·Î ¹ß»ýÇÕ´Ï´Ù. POC ¹× LOC ±â±âÀÇ ¿ëµµ´Â ´Ù¾çÇÑ È¯°æÀ¸·Î È®ÀåµÇ¾î Áï°¢ÀûÀÎ °³ÀÔ°ú Áö¼ÓÀûÀΠȯÀÚ ¸ð´ÏÅ͸µÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù. ÃÖÁ¾ »ç¿ëó´Â º´¿ø, Áø´Ü ½ÇÇè½Ç, °³ÀÎ ÀÇ·á ¼­ºñ½º, µµ½Ã¿Í ³óÃÌÀ» ¸··ÐÇÏ°í ¼­ºñ½º¸¦ Á¦°øÇÏ´Â °³ÀÎ ÀÇ·á ¼­ºñ½º µî ´Ù¾çÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ±â¼ú ¹ßÀü, ÇコÄɾ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÈÞ´ë¿ë Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, AI¿Í IoTÀÇ ÅëÇÕÀº °í±Þ Áø´Ü ±â´ÉÀ» À§ÇÑ ±æÀ» ¿­¾îÁÖ¸ç Å« ¼ºÀå ±âȸ¸¦ º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ±â¾÷Àº AI ±â¹Ý ºÐ¼® ¹× ¹ÙÀÌ¿À¼¾½Ì ±â¼ú¿¡ ÅõÀÚÇÏ¿© ±â±âÀÇ È¿À²¼º°ú »ç¿ë ÆíÀǼºÀ» Çâ»ó½ÃÅ´À¸·Î½á ÀÌ·¯ÇÑ ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº °³¹ß ºñ¿ë, ±ÔÁ¦ »óȲ, Á¦ÇÑµÈ »óȯ ȯ°æ µîÀÇ À庮ÀÌ Å« °É¸²µ¹·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇöÀçÀÇ ±â¼úÀû Á¦¾à°ú µ¥ÀÌÅÍ º¸¾È ¿ì·Á¿Í °°Àº ÇÑ°èµµ ÇØ°áÇØ¾ß ÇÕ´Ï´Ù. ¼ºÀåÀ» °¡¼ÓÇϱâ À§Çؼ­´Â ¼ÒÇüÈ­ ¼¾¼­, µ¥ÀÌÅÍ ÅëÇÕ °­È­, ½Ç½Ã°£ ºÐ¼® µîÀÇ ±â¼ú Çõ½ÅÀÌ À¯¸ÁÇÑ ºÐ¾ßÀÔ´Ï´Ù. Àúºñ¿ë Á¦Á¶ ±â¼ú ¿¬±¸°¡ ÁøÇàµÇ¸é Á¢±Ù¼ºÀÌ È®´ëµÇ°í °¡°Ý ¹Î°¨µµ°¡ ³·¾ÆÁ® »õ·Î¿î ½ÃÀåÀ» °³Ã´ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÉºÎÀü POC ¹× ½ÃÀå ¿ªÇÐ ½ÃÀåÀº ºü¸¥ ±â¼ú ¹ßÀü°ú Ä¡¿­ÇÑ °æÀïÀÌ Æ¯Â¡ÀÎ ¿ªµ¿ÀûÀÎ ½ÃÀåÀÔ´Ï´Ù. ±ÔÁ¦ °æ·Î¿¡ ´ëÇÑ ÃæºÐÇÑ ÀÌÇØ, Çù·Â °ü°è ±¸Ãà, ȯÀÚ Á᫐ ¼³°è¿¡ ÁßÁ¡À» µÎ´Â °ÍÀÌ »õ·Î¿î ±âȸ¸¦ È°¿ëÇÏ°í °úÁ¦¸¦ ±Øº¹ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 9,613¸¸ ´Þ·¯
¿¹Ãø³â[2024] 1¾ï 887¸¸ ´Þ·¯
¿¹Ãø³â[2030] 2¾ï 4,737¸¸ ´Þ·¯
CAGR(%) 14.45%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ¸·Î º¯È­ÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆľÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­ÇÏ°í, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ÀÇ·áºñ Àý°¨À» À§ÇÑ Áúº´ Á¶±â Áø´Ü¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡
    • ¼¾¼­ ¹× ±âŸ ¾×¼¼¼­¸®°¡ ÀåÂøµÈ ÀÏȸ¿ë Àúºñ¿ë LOC ÀåºñÀÇ °³¹ß Áõ°¡
    • Á¤ºÎ°¡ ´Ã¾î³ª´Â ÀÇ·áºñ ÁöÃâÀ» ÁÙÀ̱â À§ÇØ POC ¹× LOC Àåºñ äÅÃÀ» ´Ã¸®°í ÀÖ½À´Ï´Ù.
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¿©·¯ °¡Áö °Ë»ç¸¦ ¼öÇàÇÏ´Â Ä«Æ®¸®Áö°¡ ÀÖ´Â POC Àåºñ¿¡ ´ëÇÑ Ç¥ÁØ »óȯÀÌ ºÎÁ·ÇÕ´Ï´Ù.
  • ½ÃÀå ±âȸ
    • ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿ ¹ß±¼À» À§ÇÑ ¿¬±¸ È°µ¿ Áõ°¡¸¦ À§ÇÑ ±â¼ú ¹ßÀü
    • Ä¡·á ¸ð´ÏÅ͸µÀ» À§ÇÑ LOC ºÐ¼® µ¥ÀÌÅ͸¦ ºÐ¼®ÇÏ´Â »õ·Î¿î ¿¹Ãø ¸ðµ¨¸µ ±â¼ú °³¹ß
  • ½ÃÀå °úÁ¦
    • ÁÖ¹ÎÀÇ Á¢±Ù¼º ¹× ÀÎÁöµµ°¡ ¶³¾îÁü

Portre's Five Forces: ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû Åø

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡ÇÏ°í Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» È°¿ëÇÏ°í, ¾àÁ¡À» ÇØ°áÇÏ°í, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇÏ°í, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâ ÆľÇ

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ½ÉºÎÀü POC ¹× LOC Àåºñ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆľÇ

½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ º¥´õÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû Æ÷Áö¼Å´×À» ÆľÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆľÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ½ÉºÎÀü POC ¹× LOC Àåºñ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ½ÉºÎÀü POC ¹× LOC Àåºñ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®ÇÏ°í Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀåÀÇ Àü·«Àû ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇÏ°íÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ È°¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆľÇÇÏ°í, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß È°µ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå : µð¹ÙÀ̽º À¯Çüº°

  • ·¦¿Â¾îĨ(LOC) µð¹ÙÀ̽º
  • POC(Point of Care) µð¹ÙÀ̽º

Á¦7Àå ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå : Å×½ºÆ® À¯Çüº°

  • °Ô³ð °Ë»ç
  • ´ë»çüÇÐ °Ë»ç
  • ÇÁ·ÎÅ×¿È °Ë»ç

Á¦8Àå ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå : ±â¼úº°

  • Àü±âÈ­ÇÐ ¼¾½Ì
  • ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º
  • ±¤ÇÐ ¼¾½Ì

Á¦9Àå ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå : ¿ëµµº°

  • ¾î½Ã½ºÆ® ¸®ºù ÇコÄÉ¾î ½Ã¼³
  • Ŭ¸®´Ð
  • °¡Á¤
  • º´¿ø
  • ¿¬±¸½Ç

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå

  • ¾Æ¸£ÇîƼ³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ½ÉºÎÀü POC ¹× LOC µð¹ÙÀ̽º ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍÅ°
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • ACON Laboratories Inc.
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • bioMerieux SA
  • BioTelemetry, Inc. by Royal Philips
  • Boditech Med Inc.
  • Danaher Corporation
  • Eko Health, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Jant Pharmacal Corporation
  • Johari Digital India Limited
  • Lepu Medical Technology(Beijing) Co.,Ltd.
  • Lupin Limited
  • Masimo Corporation
  • Medtronic PLC
  • Novartis AG
  • Quidel Corporation
  • Sanner GmbH
  • Siemens Healthineers AG
  • Trinity Biotech PLC
  • uFluidix Inc.
KSA 24.12.03

The Heart Failure POC & LOC Devices Market was valued at USD 96.13 million in 2023, expected to reach USD 108.87 million in 2024, and is projected to grow at a CAGR of 14.45%, to USD 247.37 million by 2030.

Heart Failure Point-of-Care (POC) and Lab-on-Chip (LOC) devices have revolutionized cardiac care by enabling rapid and accurate diagnosis at the patient's location, encompassing handheld and portable devices designed for early detection. The scope of these technologies spans hospitals, clinics, and home care settings, emphasizing ease of use and timely diagnosis, which are crucial for effective heart failure management. The necessity for POC and LOC devices arises from the increasing prevalence of heart ailments driven by aging populations, lifestyle changes, and the significant healthcare burden they present. Their applications extend across various settings, facilitating immediate intervention and ongoing patient monitoring. The end-use scope includes hospitals, diagnostic laboratories, and personalized care, serving urban and rural communities alike. Key growth factors for this market include technological advancements, rising healthcare awareness, and increasing demand for portable diagnostic solutions. The integration of AI and IoT is paving the way for advanced diagnostic capabilities, marking significant growth opportunities. Companies could seize these opportunities by investing in AI-powered analytics and bio-sensing technologies to enhance device efficiency and user-friendliness. However, barriers such as high development costs, regulatory challenges, and limited reimbursement landscapes pose significant obstacles. Limitations like current technological constraints and data security concerns also need addressing. To foster growth, innovation in miniaturized sensors, enhanced data integration, and real-time analytics are promising areas. Further research in low-cost manufacturing techniques could broaden accessibility and reduce price sensitivity, unlocking new markets. The market for heart failure POC and LOC devices is dynamic, characterized by rapid technological evolution and competitive intensity. A thorough understanding of regulatory pathways, fostering collaborations, and a focus on patient-centered design will be pivotal in capitalizing on emerging opportunities and steering through challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 96.13 million
Estimated Year [2024] USD 108.87 million
Forecast Year [2030] USD 247.37 million
CAGR (%) 14.45%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Heart Failure POC & LOC Devices Market

The Heart Failure POC & LOC Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing need for early diagnosis of diseases to reduce healthcare costs
    • Growing development of disposable and low-cost LOC devices with sensors and other accessories
    • Rising adoption of POC and LOC devices by governments to alleviate the rising healthcare expenditure
  • Market Restraints
    • Lack of standard reimbursement for POC devices with a cartridge that performs multiple tests
  • Market Opportunities
    • Advancements in technology to increase research activities for the identification of novel biomarkers
    • Emerging development of predictive-modeling techniques to analyze the LOC assays data for therapy monitoring
  • Market Challenges
    • Reduced accessibility and awareness among the population

Porter's Five Forces: A Strategic Tool for Navigating the Heart Failure POC & LOC Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Heart Failure POC & LOC Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Heart Failure POC & LOC Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Heart Failure POC & LOC Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Heart Failure POC & LOC Devices Market

A detailed market share analysis in the Heart Failure POC & LOC Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Heart Failure POC & LOC Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Heart Failure POC & LOC Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Heart Failure POC & LOC Devices Market

A strategic analysis of the Heart Failure POC & LOC Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Heart Failure POC & LOC Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON Laboratories Inc., AstraZeneca PLC, Becton, Dickinson and Company, bioMerieux SA, BioTelemetry, Inc. by Royal Philips, Boditech Med Inc., Danaher Corporation, Eko Health, Inc., F. Hoffmann-La Roche Ltd., Jant Pharmacal Corporation, Johari Digital India Limited, Lepu Medical Technology(Beijing)Co.,Ltd., Lupin Limited, Masimo Corporation, Medtronic PLC, Novartis AG, Quidel Corporation, Sanner GmbH, Siemens Healthineers AG, Trinity Biotech PLC, and uFluidix Inc..

Market Segmentation & Coverage

This research report categorizes the Heart Failure POC & LOC Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Device Type, market is studied across Lab-on-a-Chip (LOC) Devices and Point-of-Care (POC) Devices.
  • Based on Test Type, market is studied across Genomic Testing, Metabolomic Testing, and Proteomic Testing.
  • Based on Technology, market is studied across Electrochemical Sensing, Microfluidics, and Optical Sensing.
  • Based on Application, market is studied across Assisted Living Healthcare Facilities, Clinics, Home, Hospitals, and Laboratory.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing need for early diagnosis of diseases to reduce healthcare costs
      • 5.1.1.2. Growing development of disposable and low-cost LOC devices with sensors and other accessories
      • 5.1.1.3. Rising adoption of POC and LOC devices by governments to alleviate the rising healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of standard reimbursement for POC devices with a cartridge that performs multiple tests
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in technology to increase research activities for the identification of novel biomarkers
      • 5.1.3.2. Emerging development of predictive-modeling techniques to analyze the LOC assays data for therapy monitoring
    • 5.1.4. Challenges
      • 5.1.4.1. Reduced accessibility and awareness among the population
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Device Type: Expanding usage of point-of-care devices in diverse settings owing to their user-friendliness
    • 5.2.2. Application: Provision of comprehensive, advanced healthcare solutions in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Heart Failure POC & LOC Devices Market, by Device Type

  • 6.1. Introduction
  • 6.2. Lab-on-a-Chip (LOC) Devices
  • 6.3. Point-of-Care (POC) Devices

7. Heart Failure POC & LOC Devices Market, by Test Type

  • 7.1. Introduction
  • 7.2. Genomic Testing
  • 7.3. Metabolomic Testing
  • 7.4. Proteomic Testing

8. Heart Failure POC & LOC Devices Market, by Technology

  • 8.1. Introduction
  • 8.2. Electrochemical Sensing
  • 8.3. Microfluidics
  • 8.4. Optical Sensing

9. Heart Failure POC & LOC Devices Market, by Application

  • 9.1. Introduction
  • 9.2. Assisted Living Healthcare Facilities
  • 9.3. Clinics
  • 9.4. Home
  • 9.5. Hospitals
  • 9.6. Laboratory

10. Americas Heart Failure POC & LOC Devices Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Heart Failure POC & LOC Devices Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Heart Failure POC & LOC Devices Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Roche Diagnostics India Launches NT-proBNP Test for Early Detection of Heart Failure in Diabetes Patients
    • 13.3.2. FDA Clears Eko Health's AI-Powered Stethoscope for Rapid Low Ejection Fraction Detection, Enhancing Early Heart Failure Diagnosis
    • 13.3.3. Roche to Acquire LumiraDx's Point-of-Care Technology in a USD 350 Million Deal, Aiming to Expand Decentralized Testing Portfolio
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ACON Laboratories Inc.
  • 3. AstraZeneca PLC
  • 4. Becton, Dickinson and Company
  • 5. bioMerieux SA
  • 6. BioTelemetry, Inc. by Royal Philips
  • 7. Boditech Med Inc.
  • 8. Danaher Corporation
  • 9. Eko Health, Inc.
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. Jant Pharmacal Corporation
  • 12. Johari Digital India Limited
  • 13. Lepu Medical Technology(Beijing)Co.,Ltd.
  • 14. Lupin Limited
  • 15. Masimo Corporation
  • 16. Medtronic PLC
  • 17. Novartis AG
  • 18. Quidel Corporation
  • 19. Sanner GmbH
  • 20. Siemens Healthineers AG
  • 21. Trinity Biotech PLC
  • 22. uFluidix Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦